Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Goss

Showing results (71-80 of 241) with videos related to

Pageof 25
Sort By:
Breast (Edinburgh, Scotland)|October 1, 2013
Extended adjuvant endocrine therapy in hormone-receptor positive breast cancerKathrin Strasser-Weippl, Tanja Badovinac-Crnjevic, Lei Fan, et al.
AIDS (London, England)|March 1, 1991
A phase II study of 4'-epirubicin in the treatment of poor-risk Kaposi's sarcoma and AIDSF A Shepherd, R L Burkes, K E Paul, et al.
American Journal of Preventive Medicine|January 1, 1992
The clerkship in public health: a positive experienceL M Drusin, M E Goss, S V Horowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study GroupP E Goss, E P Winer, I F Tannock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 1995
Inhibitors of carbohydrate processing: A new class of anticancer agentsP E Goss, M A Baker, J P Carver, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossoverHuan Jin, Dongsheng Tu, Naiqing Zhao, et al.
Oncogene|June 8, 1999
Chromosomal deletions occur in restricted regions of 5q in testicular germ cell cancerH Q Peng, L Liu, P E Goss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponadeG Liu, M Crump, P E Goss, et al.
Diabetes Care|March 1, 1995
Lower limb venous pressure in diabetic neuropathyT S Purewal, D E Goss, P J Watkins, et al.
Oncology|February 9, 1999
Rivizor--a new third-generation aromatase inhibitor for the treatment of advanced breast cancer after tamoxifen failureP E Goss, D Walde, R De Coster, et al.
Pageof 25

Showing results (71-80 of 241) with videos related to

Sort By:
Pageof 25
Breast (Edinburgh, Scotland)|October 1, 2013
Extended adjuvant endocrine therapy in hormone-receptor positive breast cancerKathrin Strasser-Weippl, Tanja Badovinac-Crnjevic, Lei Fan, et al.
AIDS (London, England)|March 1, 1991
A phase II study of 4'-epirubicin in the treatment of poor-risk Kaposi's sarcoma and AIDSF A Shepherd, R L Burkes, K E Paul, et al.
American Journal of Preventive Medicine|January 1, 1992
The clerkship in public health: a positive experienceL M Drusin, M E Goss, S V Horowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study GroupP E Goss, E P Winer, I F Tannock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 1995
Inhibitors of carbohydrate processing: A new class of anticancer agentsP E Goss, M A Baker, J P Carver, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossoverHuan Jin, Dongsheng Tu, Naiqing Zhao, et al.
Oncogene|June 8, 1999
Chromosomal deletions occur in restricted regions of 5q in testicular germ cell cancerH Q Peng, L Liu, P E Goss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponadeG Liu, M Crump, P E Goss, et al.
Diabetes Care|March 1, 1995
Lower limb venous pressure in diabetic neuropathyT S Purewal, D E Goss, P J Watkins, et al.
Oncology|February 9, 1999
Rivizor--a new third-generation aromatase inhibitor for the treatment of advanced breast cancer after tamoxifen failureP E Goss, D Walde, R De Coster, et al.
Pageof 25